DXCM : Insider Transactions for DexCom Inc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

DexCom Inc (DXCM)

$110.57

6.07 (5.2%) as of 4:30 Mon 6/24

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

389,580,000

Market Cap:

43.08(B)

Last Volume:

4,690,332

Avg Vol:

1,930,532

52 Week Range:

$75.49 - $140.45

Level I Sector:

Health Care

Level II Sector:

Health Services

Level III Sector:

Medical Instruments & Supplies

Member Indexes:

NASDAQ COMPOSITE

NASDAQ NNM COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 487

Guru Rank Value : 3

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	71,005	274,979	309,595	581,627
Total Sell Value	$9,585,020	$36,298,507	$40,264,880	$70,726,419
Total People Sold	8	10	14	16
Total Sell Transactions	13	27	50	85
End Date	2024-03-24	2023-12-22	2023-06-23	2022-06-23

Adjust Filter Settings

Records found: 2309

Page 38 of 93

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Director

– • –

2017-03-06

4

S

$78.13

$2,491,572

I/I

(31,890)

17,246

-

Director

– • –

2017-03-06

4

OE

$7.31

$233,116

I/I

31,890

49,136

-

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-02-23

4

AS

$78.42

$249,530

I/I

(3,182)

12,733

-

SVP, CFO

• – –

2017-02-22

4

AS

$78.76

$183,759

I/I

(2,333)

10,452

-

President & CEO

• • –

2017-02-17

4

AS

$81.62

$816,177

D/D

(10,000)

299,391

-

President & CEO

• • –

2017-02-17

4

OE

$8.79

$87,900

D/D

10,000

309,391

-

EVP, Clinical and Regulatory

• – –

2017-02-10

4

AS

$79.30

$253,760

D/D

(3,200)

103,872

-

EVP, Clinical and Regulatory

• – –

2017-02-10

4

OE

$9.80

$7,125

D/D

727

107,072

-

Gregg Terrance H

Executive Chairman

• • –

2017-02-09

4

D

$79.35

$112,756

D/D

(1,421)

439,845

-

CTO

• – –

2017-02-09

4

AS

$79.76

$558,316

D/D

(7,000)

72,334

-

CTO

• – –

2017-02-09

4

OE

$9.80

$68,600

D/D

7,000

79,334

-

General Manager, EMEA

• – –

2017-02-09

4

AS

$79.73

$239,204

D/D

(3,000)

70,598

-

General Manager, EMEA

• – –

2017-02-09

4

OE

$8.85

$26,550

D/D

3,000

73,598

-

CTO

• – –

2017-02-01

4

AS

$80.00

$1,112,000

D/D

(13,900)

72,334

-

CTO

• – –

2017-02-01

4

OE

$9.80

$136,220

D/D

13,900

86,234

-

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-01-23

4

AS

$79.50

$252,978

I/I

(3,182)

15,915

-

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-01-23

4

AS

$79.99

$770,908

D/D

(9,637)

110,409

-

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-01-23

4

OE

$7.79

$75,072

D/D

9,637

120,046

-

SVP, CFO

• – –

2017-01-18

4

AS

$85.01

$256,051

I/I

(3,012)

12,785

-

President & CEO

• • –

2017-01-17

4

AS

$85.94

$859,362

D/D

(10,000)

299,391

-

President & CEO

• • –

2017-01-17

4

OE

$8.79

$87,900

D/D

10,000

309,391

-

CTO

• – –

2017-01-13

4

AS

$80.00

$2,088,000

D/D

(26,100)

72,334

-

CTO

• – –

2017-01-13

4

OE

$7.63

$234,080

D/D

26,100

79,507

-

General Manager, EMEA

• – –

2017-01-13

4

AS

$79.36

$1,190,400

D/D

(15,000)

70,598

-

General Manager, EMEA

• – –

2017-01-13

4

OE

$8.85

$132,750

D/D

15,000

85,598

-

2309 Records found	Previous 30 31 32 33 34 35 36 37 38 39 Next	Page 38 of 93

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.